Dexmethylphenidate (Focalin)

Price range: $315.00 through $1,050.00

QuantityPrice
100 pellets$315.00
200 pellets$525.00
300 pellets$683.00
400 pellets$798.00
500 pellets$893.00
600 pellets$945.00
700 pellets$987.00
800 pellets$1,019.00
900 pellets$1,040.00
1000 pellets$1,050.00
SKU: Dexmethylphenidate (Focalin) Category:

What is Dexmethylphenidate?

Dexmethylphenidate is the active d-threo enantiomer of methylphenidate and is marketed as a prescription medicine under the brand name Focalin. Whereas conventional methylphenidate products generally contain a racemic mixture of d- and l-threo forms, dexmethylphenidate contains the d-threo form alone. This is a difference in stereochemistry, not a separate stimulant family.

The distinction is pharmacologically relevant because most of the central stimulant activity of methylphenidate is associated with its d-threo enantiomer. The relationship between the two medicines is discussed in the literature on methylphenidate (Ritalin) and its isomers.

Chemistry and stereochemistry

Dexmethylphenidate has the same molecular connectivity as methylphenidate. The two substances differ in the three-dimensional arrangement of atoms around their chiral centres. Methylphenidate is commonly supplied as a racemic threo mixture, while dexmethylphenidate isolates the d-threo form. That makes it possible to deliver the principal active enantiomer without the corresponding l-threo component.

Pharmacology and clinical use

Dexmethylphenidate is a central nervous system stimulant prescribed for attention-deficit/hyperactivity disorder (ADHD). It inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), reducing the reuptake of these neurotransmitters and increasing their availability outside nerve cells. The precise way in which this action produces clinical improvement in ADHD is not fully established.

In clinical treatment, the intended changes are better sustained attention and reduced hyperactivity and impulsivity. These are therapeutic outcomes observed in patients, not a description of a recreational experience. The current US prescribing information is available through the DailyMed dexmethylphenidate label.

Effects and adverse reactions

Clinical use, trials and post-marketing surveillance provide the main evidence for dexmethylphenidate’s effects and adverse reactions. Responses vary with the patient, formulation and clinical context.

Intended clinical effectsReported adverse effects
  • Attention: Improved ability to sustain attention and remain engaged with a task.
  • Impulse control: Reduced impulsivity in some patients with ADHD.
  • Activity regulation: Reduced hyperactivity and improved behavioural organisation.
  • Appetite and digestion: Reduced appetite, abdominal pain and nausea are among the commonly reported reactions.
  • Sleep: Insomnia may occur, particularly when the medicine interferes with the normal sleep schedule.
  • Cardiovascular effects: Increased heart rate and blood pressure can occur.
  • Mood and behaviour: Anxiety, restlessness, irritability and, less commonly, psychotic or manic symptoms have been reported.
  • Other effects: Headache, dizziness, weight loss and motor or vocal tics may occur.

In the paediatric clinical-trial data summarized in the prescribing information, abdominal pain, fever, reduced appetite and nausea were among the more common adverse reactions. The label also records less frequent but more serious reactions, including psychiatric symptoms and cardiovascular complications. A listed adverse event does not mean that it will occur in every patient, and spontaneous reports do not always establish a direct cause.

Medical context

Dexmethylphenidate is a regulated prescription medicine, not an unapproved research chemical. Its clinical evidence base is substantially larger than that of most methylphenidate analogues sold online. It nevertheless carries recognised risks when used outside medical supervision, including misuse and abuse, and the prescribing information includes warnings about these risks. Its therapeutic use should be distinguished from non-medical exposure to other phenidates.

Identity and Structure

Chemical NameDexmethylphenidate (Focalin)
Catalog Entity TypeCompound
FormulaC14H19NO2
Molar Mass233.311 g·mol−1
CAS40431-64-9
19262-68-1
CAS Numbers and Substance Forms40431-64-9
hydrochloride: 19262-68-1
Synonyms(2R,2′R)–(+)–methylphenidate, (αR,2R)–(+)–methylphenidate, d-threo-methylphenidate (d-TMP), d-methylphenidate (d-MPH)
IUPAC Name(R,R)-(+)-Methyl 2-phenyl-2-(2-piperidyl)acetate
InChIInChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1
InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
InChIKeyDUGOZIWVEXMGBE-CHWSQXEVSA-N
JUMYIBMBTDDLNG-OJERSXHUSA-N
SMILESO=C([C@@H]([C@@H]1NCCCC1)C2=CC=CC=C2)OC
hydrochloride: Cl.[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1

Chemical Identifiers

PubChem CID154101
154100
ChemSpider ID135807
135806
DrugBank IDDB06701
ChEBI IDCHEBI:51860
KEGG IDD07806
D03721
UNIIM32RH9MFGP
1678OK0E08
ChEMBL IDChEMBL827
ChEMBL904
IUPHAR/BPS ID7554
CompTox DTXSIDDTXSID70893769

Clinical Data

Trade NamesFocalin, Focalin XR, others
Routes of AdministrationBy mouth
ATC CodeN06BA11 (WHO)
Dependence LiabilityPhysical: None
Psychological: Moderate
Addiction LiabilityModerate
AHFS / Drugs.comMonograph
MedlinePlusa603014
License Data (Source Text)US DailyMed: Dexmethylphenidate

Pharmacokinetics

Bioavailability11–52%
Protein Binding30%
MetabolismLiver
Elimination Half-life4 hours
ExcretionKidney

Legal Status

Legal Status (Wikipedia Source Text)AU: S8 (Controlled drug)
CA: Schedule III
DE: Anlage III (Special prescription form required)
UK: Class B
US: Schedule II
UN: Psychotropic Schedule II
In general: ℞ (Prescription only)

Sources and Attribution

Wikipedia Source URLhttps://en.wikipedia.org/?curid=869864

Reviews

There are no reviews yet.

Be the first to review “Dexmethylphenidate (Focalin)”

Your email address will not be published. Required fields are marked *

Documentation

Download Certificates of Analysis

🌡 Storage Information

Keep products tightly sealed and store in a cool, dry place away from direct sunlight.

Some products require refrigeration and should be kept sealed at temperatures below 8°C. Lysergamides and tryptamines should be stored below 20°C whenever possible.

Always follow any specific storage instructions provided with the product.

🔬 Research Use Only

All products are supplied strictly for research purposes only and are not intended for human consumption.

Customers are responsible for checking the laws and regulations applicable in their country before placing an order.